A benefit-risk assessment of imatinib in chronic myeloid leukaemia and gastrointestinal stromal tumours

Drug Safety

Volumn 32, Issue 11, 2009, Pages 1001-1015

  Wolf, Dominik ^a   Rumpold, Holger ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Krankenhaus der Barmherzigen Schwestern Wien Betriebsgesellschaft   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

2 [2 METHYL 5 [4 (1 PIPERAZINYLMETHYL)BENZAMIDO]ANILINO] 4 (3 PYRIDYL)PYRIMIDINE; ALPHA INTERFERON; BCR ABL PROTEIN; BERGAMOTTIN; BUSULFAN; CLARITHROMYCIN; CYTARABINE; DASATINIB; ERYTHROMYCIN; HYDROXYUREA; IMATINIB; ITRACONAZOLE; KETOCONAZOLE; NEFAZODONE; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE; QUERCETIN; RIFAMPICIN; RITONAVIR; STEM CELL FACTOR; TELITHROMYCIN;

ABDOMINAL PAIN; ADVANCED CANCER; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; AVASCULAR NECROSIS; BLAST CELL CRISIS; BLEEDING; BONE MARROW SUPPRESSION; BONE METABOLISM; BONE NECROSIS; BREAST FEEDING; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED CANCER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG MILK LEVEL; DRUG RESPONSE; DRUG SAFETY; DRUG SENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; FLUID RETENTION; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HUMAN; HYPEREOSINOPHILIC SYNDROME; HYPOPHOSPHATEMIA; INFECTION; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; METASTASIS; MUSCLE CRAMP; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; PATIENT COMPLIANCE; PREGNANCY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RISK BENEFIT ANALYSIS; SARCOMA; SIDE EFFECT; SKIN EXFOLIATION; STEM CELL TRANSPLANTATION; SYSTEMIC MASTOCYTOSIS; SYSTOLIC HEART FAILURE; THROMBOCYTOPENIA; VOMITING; WEIGHT GAIN;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST FEEDING; DRUG DELIVERY SYSTEMS; DRUG INTERACTIONS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PYRIMIDINES;

EID: 70349972513     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11314600-000000000-00000     Document Type: Review

References (59)

1. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411 (6835): 355-365
2. Sawyers C. Targeted cancer therapy. Nature 2004; 432 (7015): 294-297
3. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105 (7): 2640-2653
4. Druker BJ, Guilhot F, O?Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355 (23): 2408-2417
5. Branford S, Seymour JF, Grigg A, et al. BCR-ABL mes-senger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with im-atinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res 2007; 13 (23): 7080-7085
6. Hochhaus A, Druker BJ, Larson RA, et al. IRIS 6-year follow-up: sustained survival and declining annual rate of transformation in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract]. ASH Annual Meeting Abstracts 2007; 110 (11): 25
7. Baccarani M, Saglio G, Goldman J, et al. European Leu-kemiaNet. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood 2006 Sep 15; 108 (6): 1809-1820
8. Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharma-cokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008; 111 (8): 4022-4028
9. White D, Saunders V, Grigg A, et al. Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. J Clin Oncol 2007; 25 (28): 4445-4451
10. White DL, Saunders VA, Dang P, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007; 110 (12): 4064-4072
11. Jiang X, Saw KM, Eaves A, et al. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. J Natl Cancer Inst 2007; 99 (9): 680-693
12. Cortes J, Giles F, Salvado AJ, et al. Molecular responses in newly diagnosed chronic myelocytic leukemia (CML) patients treated with 800 mg imatinib daily: an update from the RIGHT Trial Study Group [abstract]. ASH Annual Meeting Abstracts 2006; 108 (11): 2149
13. Kantarjian H, Talpaz M, O?Brien S, et al. High-dose im-atinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004; 103 (8): 2873-2878
14. Hughes TP, Branford S, White DL, et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of im-atinib as initial therapy. Blood 2008; 112 (10): 3965-3973
15. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007 Jan 1; 109 (1): 58-60
16. Carella AM, Lerma E. Durable responses in chronic mye-loid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission. Ann Hematol 2007 Oct; 86 (10): 749-752
17. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99 (6): 1928-1937 (Pubitemid 34525471)
18. Kantarjian H, Talpaz M, O?Brien S, et al. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukaemia: comparison with historic experience. Cancer 2005 May 15; 103 (10): 2099-2108
19. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib in-duces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99 (10): 3530-3539 (Pubitemid 34534519)
20. Kantarjian HM, Cortes J, O?Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002; 99 (10): 3547-3553 (Pubitemid 34534521)
21. Cortes J, Kim DW, Raffoux E, et al. Efficacy and safety of dasatinib in imatinib-resistant or-intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008; 22 (12): 2176-2183
22. Hochhaus A, Druker B, Sawyers C, et al. Favorable long-term follow-up results over six years for response, survival and safety with imatinib mesylate therapy in chronic phase chronic myeloid leukemia post failure of interferon-alpha treatment. Blood 2007; 111 (3): 1039-1043
23. Champagne MA, Capdeville R, Krailo M, et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children?s Oncology Group phase 1 study. Blood 2004; 104 (9): 2655-2660
24. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gas-trointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33 (5): 459-465 (Pubitemid 34747864)
25. Miettinen M, Lasota J. Gastrointestinal stromal tumors: definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438 (1): 1-12
26. Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastro-intestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era: a population-based study in western Sweden. Cancer 2005; 103 (4): 821-829
27. Corless CL, Fletcher JA, Heinrich MC. Biology of gastro-intestinal stromal tumors.J Clin Oncol 2004;22(18): 3813-3825
28. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mu-tations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21 (23): 4342-4349
29. Weisberg E, Manley PW, Breitenstein W, et al. Character-ization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7 (2): 129-141
30. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347 (7): 472-480
31. Blanke CD, Demetri GD, Von Mehren M, et al. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with un-resectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26 (4): 620-625 (Pubitemid 351264357)
32. Blanke CD, Rankin C, Demetri GD, et al. Phase III ran-domized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26 (4): 626-632
33. Van Glabbeke MM, Owzar K, Rankin C, et al. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): a meta-analyis based on 1,640 patients (pts) [abstract]. J Clin Oncol 2007; 25 (18 Suppl.): 10004
34. Van Glabbeke M, Verweij J, Casali PG, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol 2005; 23 (24): 5795-5804
35. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364 (9440): 1127-1134
36. Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373 (9669): 1097-1104
37. Zhan WH. Efficacy and safety of adjuvant post-surgical therapy with imatinib in patients with high risk of relapsing GIST [abstract]. China Gastrointestinal Cooperative Group. J Clin Oncol 2007; 25 (18S): 10045
38. Nilsson B, Sjolund K, Kindblom LG, et al. Adjuvant im-atinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST). Br J Cancer 2007; 96 (11): 1656-1658
39. Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year. The French Sarcoma Group. J Clin Oncol 2007; 25 (9): 1107-1113
40. Eisenberg BL, Harris J, Blanke CD, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol 2009; 99 (1): 42-47
41. Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008; 26 (33): 5360-5367
42. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT muta-tions and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42 (8):1093-1103
43. Demetri GD, Benjamin RS, Blanke CD, et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST). Update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 2007; 5 Suppl. 2: S1-29
44. Casali PG, Jost L, Reichardt P, et al. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19Suppl. 2:ii35-8
45. O?Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348 (11): 994-1004
46. Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12 (8): 908-916
47. Atallah E, Durand JB, Kantarjian H, et al. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007; 110 (4): 1233-1237
48. Fitter S, Dewar AL, Kostakis P, et al. Long term imatinib therapy promotes bone formation in CML patients. Blood 2007; 111 (5): 2538-2547
49. Fabarius A, Haferlach C, Muller MC, et al. Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure. Haematologica 2007; 92 (6): 834-837
50. van Oosterom AT, Judson I, Verweij J, et al. Safety and effi-cacy of imatinib (STI571) in metastatic gastrointestinal stro-mal tumours: a phase Istudy. Lancet 2001; 358 (9291): 1421-3
51. Data on file, Novartis Ault P, Kantarjian H, O?Brien S, et al. Pregnancy among patients with chronic myeloid leukemia treated with im-atinib. J Clin Oncol 2006; 24 (7): 1204-1208 (Pubitemid 46638819)
52. AlKindi S, Dennison D, Pathare A. Imatinib in pregnancy. Eur J Haematol 2005; 74 (6): 535-537
53. Choudhary DR, Mishra P, Kumar R, et al. Pregnancy on imatinib: fatal outcome with meningocele. Ann Oncol 2006; 17 (1): 178-179
54. Bazarbashi MS, Smith MR, Karanes C, et al. Successful management of Ph chromosome chronic myelogenous leukemia with leukapheresis during pregnancy. Am J Hematol 1991; 38 (3): 235-237
55. Mubarak AA, Kakil IR, Awidi A, et al. Normal outcome of pregnancy in chronic myeloid leukemia treated with inter-feron-alpha in 1st trimester: report of 3 cases and review of the literature. Am J Hematol 2002; 69 (2): 115-118
56. Russell MA, Carpenter MW, Akhtar MS, et al. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk. J Perinatol 2007; 27 (4): 241-243
57. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231 (1): 51-58
58. Gold JS, van der Zwan SM, Gonen M, et al. Outcome of metastatic GIST in the era before tyrosine kinase inhibitors. Ann Surg Oncol 2007; 14 (1): 134-142
59. Rossi CR, Mocellin S, Mencarelli R, et al. Gastrointestinal stromal tumors: from a surgical to a molecular approach. Int J Cancer 2003; 107 (2): 171-176